CEL-SCI Corp's (CVM) Multikine Phase 3 Trial Receives FDA Clinical Hold

CEL-SCI Reports Clinical Hold on Head and Neck Cancer Study

VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (NYSE MKT: CVM) announced today that it has received verbal notice from the U.S. Food and Drug Administration (FDA) that its Multikine (Leukocyte Interleukin Injection) Phase 3 clinical trial in advanced primary head and neck cancer has been placed on clinical hold. Pursuant to this communication from FDA, patients currently receiving study treatments can continue to receive treatment, and patients already enrolled in the study will continue to be followed. CEL-SCI was also told to expect a formal letter from the FDA within 30... More